Showing results (191-200 of 215) with videos related to
Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastomaWolfgang Wick, Vinay K Puduvalli, Marc C Chamberlain, et al.Genome Biology|January 23, 2015
Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genesAkash Kumar, Evan A Boyle, Mari Tokita, et al.Neuro-Oncology|March 5, 2008
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesMorris D Groves, Michael J Glantz, Marc C Chamberlain, et al.Neuro-Oncology|May 23, 2018
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working GroupNils D Arvold, Terri S Armstrong, Katherine E Warren, et al.Elife|September 27, 2018
Sparse recurrent excitatory connectivity in the microcircuit of the adult mouse and human cortexStephanie C Seeman, Luke Campagnola, Pasha A Davoudian, et al.The Journal of Clinical Investigation|August 9, 2014
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patientsJennifer E Adair, Sandra K Johnston, Maciej M Mrugala, et al.Plos One|October 29, 2014
Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomasAnne L Baldock, Sunyoung Ahn, Russell Rockne, et al.Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.Neuro-Oncology|February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon, Evanthia Galanis, John F DeGroot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupPatrick Y Wen, David R Macdonald, David A Reardon, et al.Pageof 22